India signs 300 million-dose deal with company developing national Kovid-19 vaccine

class = “cf”>

According to the information in the Times of India newspaper, in the statement made by the Ministry of Health of India, it was reported that the company’s future proposal to be delivered in August-December 2021 was accepted with the Approval of the National Expert Group for Vaccine Management (NEGVAC).

In the statement, it was noted that an agreement had been signed with Biological-E to receive 300 million doses of the Kovid-19 vaccine, which is still in third-phase clinical trials, and it was reported that 15 billion rupees (approximately $ 205 million) will be paid to the company for vaccines.

The protein-based vaccine developed by Biological-E in collaboration with Baylor University School of Medicine in Texas, USA, aims to boost immunity by artificially producing the receptor-binding protein that allows the virus to attach to human cells.

In India, emergency use approval was given to the Kovid-19 vaccine developed by the University of Oxford with the pharmaceutical company AstraZeneca, the national vaccine jointly developed by the Bharat Biotech company and the Indian Research Council medicine, and Russia’s Sputnik V vaccine.

class = “cf”>

In addition to Bharat Biotech and Biological-E in India, Zydus Cadila, Indian Serum Institute (SII) and Panacea Biotec are also working on the development of national vaccines. Zydus Cadila is testing the COVID-19 vaccine candidate “ZyCoV-D” on humans in clinical trials.

Bigpara for cryptocurrency markets

Bigpara for cryptocurrency markets

Add a Comment